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BRIEF REPORT: TRANSLATIONAL RESEARCH
HIV Antibodies Decline During Antiretroviral Therapy but
Remain Correlated With HIV DNA and HIV-Specific T-Cell
Responses
Sheila M. Keating, PhD,a,b Richard Brad Jones, PhD,c Christina M. Lalama, MS,d Ronald J. Bosch, PhD,d
Deborah McMahon, MD,e Dylan Hampton, BS,a Joshua Cyktor, PhD,e Joseph J. Eron, MD,f
John W. Mellors, MD,e Michael P. Busch, MD, PhD,a,b and Rajesh T. Gandhi, MD,g the ACTG 5321 Team
Background: In people with HIV on antiretroviral therapy (ART),
the relationship between HIV-specific immune responses and
measures of HIV persistence is uncertain.
Methods: We evaluated 101 individuals on suppressive ART in the
AIDS Clinical Trials Group A5321 cohort. Cell-associated (CA)
HIV DNA and RNA levels and HIV antibody concentrations and
avidity to Env/p24 were measured longitudinally at years 1, 4, and
6–15 after ART initiation. Plasma HIV RNA by single copy assay
and T-cell responses (IFN-g ELISPOT) against multiple HIV
antigens were measured at the last time point.
Results: HIV antibody levels declined significantly with increasing
time on ART (19%/year between year 1 and 4). HIV antibody levels
correlated with T-cell responses to HIV Pol (r = 0.28, P = 0.014) and
to Nef/Tat/Rev (r = 0.34; P = 0.002). HIV antibody and T-cell
responses were positively associated with HIV DNA levels; for
example, at the last time point (median 7 years on ART), r = 0.35 for
antibody levels and HIV DNA (P , 0.001); r = 0.23 for Nef/Tat/
Rev-specific T-cell responses and HIV DNA (P = 0.03). Neither
antibody nor T-cell responses correlated with cell-associated HIV
RNA or plasma RNA by single copy assay.
Conclusions: In individuals on long-term ART, HIV-specific
antibody and T-cell responses correlate with each other and with
HIV DNA levels. The positive correlation between HIV immune
responses and HIV DNA implies that the immune system is sensing,
but not clearing, infected cells, perhaps because of immune
dysfunction. Measuring immune responses to HIV antigens may
provide insight into the impact of reservoir-reducing strategies.
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INTRODUCTION
In people with HIV, antiretroviral therapy (ART)
suppresses plasma HIV RNA to levels below the limits of
detection of commercial assays,1 but a reservoir of latently
infected cells persists that leads to HIV rebound if ART is
stopped.2 A measure of the latently infected cell population in
people on ART is cell-associated HIV DNA, which is
comprised of intact and defective proviruses. Because
defective proviruses rapidly accumulate soon after HIV
acquisition, only a small fraction of proviruses is intact3
and potentially replication-competent; as a result, HIV DNA
is considered to be a maximal measure of the HIV reservoir.
Latently infected HIV DNA-containing cells have previously
been thought to not express antigen and, therefore, to be
invisible to the immune system. There are recent data,
however, indicating that intact and defective HIV proviruses
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are transcribed, leading to the possibility of intermittent
antigen expression in people on ART.4
HIV-specific immune responses usually decline after
ART is initiated, because of decreasing levels of viral
antigen.5,6 For example, over the first one to 2 years of
ART, HIV-specific CD8 T-cell responses declined by median
52% per year (half-life 49.8 weeks, based on 5 individuals).7
However, if there is intermittent antigen expression and
recognition, HIV antibody and T-cell responses may be elicited
and maintained. Understanding the longitudinal relationship
between HIV-specific immune responses and measures of HIV
persistence may provide insight into whether the immune
response continues to sense infected cells in people on ART. In
addition, if HIV-specific immune responses correlate with the
number of infected cells during ART, tracking these responses
may provide information on the impact of interventions
designed to stimulate virus expression or reduce HIV
reservoirs.8–10 To understand the relationship between HIV-
specific antibody responses and measures of HIV persistence,
we conducted a longitudinal study in a large cohort of
participants on long-term suppressive ART.
METHODS
Study Population
We evaluated participants with chronic HIV infection
who initiated ART in AIDS Clinical Trials Group (ACTG)
studies and had subsequent follow-up specimens while con-
tinuing to receive ART (ACTG studies A5001 and A532111).
Participants had HIV RNA ,50 copies/mL by commercial
assays at or before week 48 of ART and at all subsequent time
points and no reported ART interruptions. Informed consent
was obtained from participants, and human experimentation
guidelines of the US Department of Health and Human
Services were followed in the conduct of clinical research.
Virologic Assays
Cell-associated (CA) HIV DNA and unspliced HIV
RNA levels (using quantitative PCR targeting HIV pol) in
peripheral blood mononuclear cells were measured longitu-
dinally before initiation of ART and on-ART years 1, 4, and
(for some participants) 6–15 years using previously described
methods.11,12 Primers and probes used for qPCR of HIV
DNA, CA-RNA, and plasma HIV RNA were identical.
Testing of the cellular housekeeping gene, IPO8, served as
an internal control for mRNA recovery. Results were ex-
pressed as copies/million CD4+ T-cells normalized for %
CD4+T-cells in blood. Plasma HIV RNA by single copy
assay (SCA) was measured on samples from the last on-ART
time point using a previously reported method.13
HIV Antibody Assays
HIV antibodies were measured at years 1, 4 and, for
some participants, years 6–15 after ART initiation using
assays that have been previously described.8 Less-sensitive
(LS) and Avidity-modified VITROS HIV 1 + 2 were used to
measure antibodies against HIV envelope (Env) and p24
(Gag).8 Limiting Antigen (Lag)-Avidity EIA was performed
as previously described.14 The assays for HIV antibodies used
in this study are FDA-cleared diagnostic tests that provide
reproducible clinical measurements over time and across
assay lots; the performance characteristics have been
published.15,16
T-Cell Responses Measured by IFN-g ELISPOT
HIV interferon-gamma ELISPOT assays were per-
formed as previously described and reported on samples
from the last on-ART time point.9 In brief, Multiscreen IP 96-
well plates (Millipore) were coated with 0.5 mg/mL of anti-
interferon-gamma antibody (clone 1-D1K, MAbtech,
Sweden) in phosphate-buffered saline and incubated over-
night. Plates were washed, peripheral blood mononuclear
cells were added at 2 · 105 cells per well and HIV peptide
pools (10 mg/mL/peptide) and phytohemaggultinin (2 mg/mL)
were added. Plates were incubated overnight, washed and
secondary antibody was added (clone 7-B6-1, Mabtech) and
incubated for 1 hour. Plates were developed with
Streptavidin-ALP (MAbtech) and developed with Color
Development buffer (Bio-Rad, Hercules, CA). Plates were
washed, dried overnight and spots were counted.
Statistical Analysis
Rank-based correlations (Spearman) and rank-sum test
were used. Results below assay limits were assigned the lowest
rank. Within-participant change per year between years 1–4 on
ART in log10-transformed measures of HIV antibody were
estimated with participant-specific linear regression models.
Changes over time were compared against the null hypothesis
of no change using the Wilcoxon signed-rank test.
RESULTS
Study Population
A total of 101 participants who initiated ART underwent
longitudinal testing of HIV antibodies and measurements of
HIV DNA and CA-RNA. The median age at ART initiation
was 39 years; 21% were female. Participants had a median of 7
years on ART (minimum, maximum: 4, 15) at the time of the
last sample collection. Median pre-ART CD4+ and CD8+
T-cell counts were 290 and 792 cells/mm3, respectively. At the
time of the last blood collection, median CD4+ and CD8+
T-cell counts were 681 and 699 cells/mm3, respectively.
Median pre-ART HIV RNA was 4.6 log10 copies/mL. All
participants had plasma HIV RNA levels,50 copies/mL at all
time points at or after week 48 of ART. Additional details
regarding the cohort have been previously published.11
HIV Antibodies Decline During Long-
Term ART
There was a strong correlation between antibody
level (as measured by signal to cutoff ratio) and avidity at
each on-treatment time point (all r $ 0.95, P , 0.001; see
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Supplemental Figure 1, Supplemental Digital Content,
http://links.lww.com/QAI/B327).
HIV antibodies declined significantly with increas-
ing time on ART (Fig. 1A): between years 1 and 4 on
ART, antibody levels declined by median 19%/year and
avidity declined by median 5.6%/year (P-values , 0.001).
Ninety-nine percent of participants had a negative anti-
body level slope and 96% had a negative avidity slope.
Participants with higher HIV antibody levels and avidity
at year 1 of ART had higher levels and avidity at year 4 of
ART (r = 0.97 and 0.96, respectively; P , 0.001) (see
Supplemental Figure 2, Supplemental Digital Content 2,
http://links.lww.com/QAI/B327).
HIV Antibodies and Pre-ART Characteristics
At year 1 of ART, higher HIV antibody levels and
avidity were modestly correlated with older age (r = 0.23 and
r = 0.23, P , 0.05, respectively), but not participant sex (P $
0.37). Of the 101 participants, 21% were female; this number
may be too low to assess differences in antibody responses by
sex. There were no significant correlations observed between
HIV antibody level or avidity at year 1 on ART with pre-ART
plasma HIV RNA, pre-ART HIV DNA, pre-ART CA-RNA,
pre-ART CD4 cell count, or pre-ART CD4:CD8 ratio (all P-
values $ 0.08).
HIV Antibody Responses Correlate With
T-Cell Responses Directed Against Nef/Tat/
Rev and Pol
HIV ELISPOT assays were performed at the last time
point after ART initiation (median of 7 years) and
compared with antibody levels and avidity at the same
time point (Fig. 2). HIV antibody and avidity correlated
with T-cell responses to all HIV peptides (r = 0.27, P =
0.02 and r = 0.27, P = 0.02, respectively). HIV antibody
levels and avidity also correlated with T-cell responses to
HIV Pol (r = 0.28, P = 0.014 and r = 0.25, P = 0.024,
respectively) and to Nef/Tat/Rev (r = 0.34, P = 0.002 and r
= 0.34, P = 0.002). There were no correlations between
HIV antibody and T-cell responses to HIV Gag or Env, or
to CMV and EBV controls.
HIV Antibody and T-Cell Responses on ART
Correlate With HIV DNA
At year 1 of ART, HIV antibody level and avidity were
positively correlated with HIV DNA (r = 0.24 and 0.27,
respectively; P , 0.02). Similarly, at year 4 on ART, both
HIV antibody measures were correlated with HIV DNA (r =
0.31 and 0.36, P# 0.002, respectively). At the last time point
(median of 7 years on ART), antibody level and avidity
FIGURE 1. HIV antibody levels and avidity decline with time on antiretroviral treatment and correlate with HIV DNA levels. Lines
correspond to longitudinal antibody responses for each participant (n = 101). Gray lines represent the median and interquartile
range. Antibody levels were measured using the LS-Vitros signal/cut-off (S/Co) ratio. Antibody avidity was measured by the vitros
avidity index (AI). A, LS-VITROS S/co and AI results over time on ART. Between years 1 and 4 on ART, antibody levels declined by
median 19%/year (1.23-fold/year) and avidity declined by median 5.6%/year (1.06-fold/year) (P-values , 0.001). B, Correlation
of LS-VITROS and AI with HIV DNA/106 CD4+T cells at the last longitudinal time point (n = 96).
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continued to be correlated with HIV DNA levels (r = 0.35 and
0.38, respectively, P , 0.001; Fig. 1B). Similarly, at the last
time point, Nef/Tat/Rev-specific T-cell responses correlated
with HIV DNA levels (r = 0.23, P = 0.03), as previously
reported.9
HIV antibody levels and avidity were not significantly
correlated with CA-RNA (measured at years 1 and 4; P $
0.24) and were not significantly correlated with plasma HIV
RNA by SCA (measured at year 4–15). Similar to the results
for HIV antibodies, at the last time point (as previously
reported9), T-cell responses did not correlate with CA-RNA
or plasma HIV RNA by SCA.
DISCUSSION
In this longitudinal study, we found that HIV
antibody levels and avidity declined significantly during
ART. HIV antibody levels correlated with T-cell responses
to HIV Pol and Nef/Tat/Rev. Despite many years of ART,
during which plasma HIV RNA was consistently sup-
pressed to ,50 copies/mL, we found that HIV antibody
and T-cell responses were positively correlated with HIV
DNA levels. The positive correlation between HIV
immune responses and HIV DNA implies that the immune
system is sensing, but not clearing, infected cells, perhaps
because of functional defects in immune responses or
resistance of infected cells to elimination (both of which
have been described in previous studies in ART-treated
individuals.17,18)
Before initiation of ART, viral replication and
antigen production induce HIV-specific antibody and
T-cell responses. The decline in immune responses after
initiation of ART is expected, given the reduced levels of
HIV production in persons on suppressive ART. In fact, the
latently infected cell population that persists in people on
long-term ART has been thought to be invisible to the
immune system. Some HIV-infected cells, however, are
releasing intact viral particles that can be detected in
plasma by single-copy assay,1 and recent findings that
defective HIV proviruses are transcribed provides another
avenue by which antigen expression may occur in people
on ART.4 Our findings that HIV antibody responses and
our previous report that T-cell responses9 correlate with
HIV DNA levels supports the hypothesis that there is
intermittent antigen production during ART19 that main-
tains immune responses against the virus.
A strength of this study is that participants had
documented sustained suppression of plasma HIV RNA for
FIGURE 2. HIV antibody levels and avidity corre-
late with HIV antigen-specific T-cell responses.
Each data point represents the antibody meas-
urements or the number of antigen-specific IFN-g
spot-forming T-cell responses for each participant.
Shown are correlations between IFN-g-producing
HIV-specific T-cell responses and LS-VITROS or AI
measurements of antibody. Top panels are T-cell
responses to pol, middle panels are responses to
Nef/Tat/Rev, and bottom panels are T-cell re-
sponses to total HIV.
J Acquir Immune Defic Syndr  Volume 81, Number 5, August 15, 2019 HIV Antibodies and Persistence During ART
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. www.jaids.com | 597
many years after treatment initiation, allowing us to assess the
relationship between immune responses and HIV persistence
without potential confounding that may result from transient
detectable viremia or virologic failure. The finding that
antibody levels and avidity—and the previous finding that
HIV-specific T-cell responses—are correlated with HIV
DNA, but not CA-RNA or low-level plasma viremia, was
unexpected. One potential explanation is that the number of
infected cells, as measured by HIV DNA, reflects the
likelihood of intermittent antigen production and induction
of immune responses better than CA-RNA, because of blocks
in nuclear export or translation. Another possibility is that
blood levels of CA-RNA and HIV RNA by SCA may not
reflect cumulative in vivo antigenicity, perhaps because of
fluctuations in RNA levels over time, varying copy numbers
per cell and/or antigen production in lymphoid or
other compartments.
The current findings should be considered in light of the
results of a previous study performed on the same set of
samples, which reported a direct correlation between HIV-
specific T-cell responses and HIV DNA.9 The correlation was
unique to T-cell responses directed against Nef, with no
correlations detected for T-cell responses to other gene
products, including Gag and Env. In this study, there was
a correlation between antibody responses to Gag/Env and
HIV DNA (we did not measure antibody responses to Nef).
Gag/Env-specific antibody responses correlated strongly with
Nef-specific T-cell responses, but not with Gag- or Env-
specific T-cell responses. We propose 2 potential explana-
tions: (1) Nef-mediated immune-evasion through MHC class
I down-regulation20 may prevent T cells, but not B cells, from
sensing late gene products, such as Gag and Env, produced by
infected HIV DNA-positive cells; (2) long-term antigen
exposure and paucity of CD8 cells to clear HIV-infected
cells in the B cell follicle may drive a differential B and T-cell
immune response.21 Further study is needed to distinguish
among these and other possibilities.
HIV antibodies have been proposed as a method to
monitor HIV persistence in people on ART.8 Here we show
that there are significant declines in antibody levels and
avidity in almost all persons on ART, likely because of the
loss of stimulating antigens.22 One limitation is that we were
not able to test pre-ART specimens for antibody; as a result,
we cannot assess changes in these measures during the first
year of ART. However, a cross-sectional analysis of a separate
cohort by our group supports the finding that antibodies
correlate with measures of HIV persistence during treatment.8
In addition, quantitative HIV-specific antibodies were
recently reported to correlate with HIV DNA levels in
children on ART,10 leading the authors to similarly propose
their use for monitoring HIV persistence.
Another study limitation is that the cohort started ART
at a lower CD4 cell count (median 290/mm3) than is typical
currently and with regimens that include older medications.
This CD4 cell count nadir may be lower than current values,
but there is still a substantial proportion of people in the
United States who have a CD4 cell count ,200/mm3 at time
of diagnosis (about 25% in a recent study).23 In ART
regimen, approximately 50% of study participants received
a non-nucleoside reverse transcriptase inhibitor, 30% received
a protease inhibitor, and 20% received an integrase inhibi-
tor.11 Even though integrase inhibitors are used more widely
now than in the past, differences in regimen are unlikely to
affect immune responses in people with sustained virologic
suppression, as in our cohort.
In conclusion, in persons on long-term ART, HIV-
specific antibody and T-cell responses correlate with each
other and with HIV DNA levels. The positive correlation
between HIV immune responses and HIV DNA suggests that
the immune system may be periodically sensing, but not
efficiently clearing, infected cells, perhaps because of
immune dysfunction. Sensing of infected cells by immune
responses suggests that tracking these measures may be
a method of assessing the impact of novel reservoir-
reducing strategies.
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